Matinas BioPharma Holdings, Inc. (MTNB) - Dilution Analysis

10-Q filing | 6.4M shares outstanding

10-K filing | 6.4M shares outstanding

10-Q filing | 6.4M shares outstanding

8-K filing: Matinas BioPharma Holdings, Inc. issued 466,666 shares of common stock in exchange for warrants to purchase the same number of shares, with the warrants subsequently cancelled.

10-Q filing | 5.1M shares outstanding

S-3 filing: This S-3 filing relates to the resale of up to 16,894,212 shares of common stock by selling stockholders, consisting of shares issuable upon conversion of preferred stock and exercise of warrants issued in a private placement.

10-K filing | 4.9M shares outstanding

8-K filing: Matinas BioPharma Holdings, Inc. completed the second and final closing of a private placement, selling 1,650 shares of Series C Convertible Preferred Stock and accompanying Warrants for gross proceeds of $1.65 million. ($0.0M proceeds)

8-K filing: Matinas BioPharma Holdings, Inc. entered into a Securities Purchase Agreement to issue and sell 3,300 shares of Series C Convertible Preferred Stock and warrants to purchase common stock in a private placement, with an initial closing of 1,650 shares of Preferred Stock and warrants for gross proceeds of $1.65 million. ($3.3M proceeds)

10-Q filing | 5.0M shares outstanding

8-K filing: Stock split 1-for-50 | Outstanding: 249,350,963 → 4,987,019

10-Q filing | 249.4M shares outstanding

10-Q filing | 250.8M shares outstanding

8-K filing: Matinas BioPharma Holdings, Inc. entered into a securities purchase agreement for the sale and issuance of 33,333,334 shares of common stock and warrants to purchase up to 33,333,334 shares at a price of $0.30 per share and accompanying warrant, resulting in gross proceeds of approximately $10 million. ($20.0M proceeds)

10-K filing | 217.3M shares outstanding

10-Q filing | 217.3M shares outstanding

10-Q filing | 217.3M shares outstanding

S-3 filing: The company is filing an S-3 to offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, warrants, debt securities, subscription rights or units having an aggregate initial offering price not exceeding $200,000,000.

10-Q filing | 217.3M shares outstanding

10-K filing | 216.8M shares outstanding

10-Q filing | 216.9M shares outstanding

10-Q filing | 216.9M shares outstanding

10-Q filing | 216.6M shares outstanding

10-K filing | 216.9M shares outstanding

10-Q filing | 216.2M shares outstanding

10-Q filing | 214.7M shares outstanding

10-Q filing | 204.3M shares outstanding

10-K filing | 204.3M shares outstanding

10-Q filing | 199.2M shares outstanding

10-Q filing | 198.9M shares outstanding

S-3/A filing: The filing is an S-3/A form indicating a potential offering of common stock, preferred stock, warrants, debt securities, subscription rights or units with an aggregate initial offering price not exceeding $200,000,000, and common stock offered by us: Shares of our common stock having an aggregate offering price of up to $50,000,000.

S-3 filing: The company is filing an S-3 to offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, warrants, debt securities, subscription rights or units having an aggregate initial offering price not exceeding $200,000,000.

10-Q filing | 163.2M shares outstanding

10-K filing | 113.3M shares outstanding

8-K filing: Matinas BioPharma Holdings, Inc. entered into an underwriting agreement with Piper Sandler & Co. for the offering, issuance, and sale of 32,260,000 shares of common stock at a price of $1.55 per share, with expected net proceeds of approximately $46.5 million. ($49.99M proceeds)